GlaxoSmithKline Profit Margin

GSK -- USA Stock

Report: 22nd of July 2020

GlaxoSmithKline PLC profit margin fundamental analysis lookup allows you to check this and other indicators for GlaxoSmithKline PLC or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Profit Margin

Refresh

GlaxoSmithKline PLC EBITDA Margin is decreasing as compared to previous years. The last year's value of EBITDA Margin was reported at 0.19.

GlaxoSmithKline Profit Margin Analysis

Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

Net Income

Revenue

100

More About Profit Margin | All Equity Analysis

Current GlaxoSmithKline PLC Profit Margin

15.29 %

GlaxoSmithKline Profit Margin Over Time Pattern

GlaxoSmithKline PLC Profit Margin

Timeline

About Profit Margin

In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.

Compare to competition

Predict GlaxoSmithKline PLC

Profit Margin Over Time

GlaxoSmithKline PLC Profit Margin Related Assessment

Operating Margin

Based on the latest financial disclosure GlaxoSmithKline PLC has Profit Margin of 15.29%. This is 236.4% lower than that of the Healthcare sector and significantly higher than that of Drug Manufacturers?General industry. The profit margin for all United States stocks is notably lower than that of the firm.

Did you try this?

Run Companies Directory Now

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

All Next

Launch Module

GlaxoSmithKline PLCCurrent Valuation Drivers

	2014	2015	2016	2017	2018	2019	2020 (projected)
Revenue Per Employee	234.94 K	236.26 K	280.09 K	306.57 K	322.77 K	339.45 K	297.49 K
Average Assets	41.37 B	47.05 B	56.26 B	57.73 B	57.22 B	68.88 B	64.51 B
Earnings before Tax	2.89 B	10.58 B	1.79 B	2.89 B	4.38 B	5.6 B	5.21 B
Average Equity	5.63 B	4.69 B	3.12 B	528 M	1.86 B	7.59 B	6.44 B
Enterprise Value	135.45 B	130.34 B	118.87 B	112.37 B	121.13 B	155.97 B	157.75 B
Free Cash Flow	5.13 B	3.32 B	6.66 B	6.99 B	8.57 B	8.36 B	8.31 B
Invested Capital	29.76 B	29 B	29.23 B	19.77 B	34.77 B	39.93 B	37.66 B
Tangible Asset Value	28.61 B	31.61 B	34.34 B	33.09 B	35.08 B	38.17 B	38.38 B
Working Capital	1.38 B	3.17 B	(2.29 B)	(10.66 B)	(5.56 B)	(4.56 B)	(4.68 B)
Interest Coverage	5.28	16.12	3.49	5.68	136.42	146.89	158.48
Calculated Tax Rate	4.66	20.49	45.35	38.61	15.81	15.5	23.02
PPandE Turnover	2.57	2.56	2.72	2.79	2.81	3.15	3.33
Receivables Turnover	4.73	4.99	5.08	5.32	5.25	5.21	4.85
Inventory Turnover	2.18	1.8	1.98	1.89	1.94	1.86	2.08
Operating Margin	14.29	41.77	7.89	12.36	16.82	19.58	22.25
Return on Investment	13.61	44.62	10.56	20.2	21.85	18.28	23.2
Cash Flow Per Share	1.06	0.53	1.32	1.4	1.7	1.61	1.37
Revenue to Assets	0.57	0.45	0.47	0.54	0.53	0.42	0.55
Quick Ratio	0.66	0.83	0.56	0.36	0.45	0.48	0.63
Asset Turnover	0.63	0.56	0.51	0.5	0.52	0.54	0.49
Book Value per Share	1.6	1.91	0.42	(0.025)	1.41	4.24	4.57
Current Ratio	1.1	1.24	0.88	0.6	0.75	0.81	0.86
Debt to Equity Ratio	8.38	8.72	48.15	(777.82)	14.39	5.38	5.8
Dividend Yield	0.062	0.061	0.072	0.058	0.056	0.043	0.0541
EBITDA Margin	0.16	0.47	0.091	0.12	0.17	0.19	0.2

GlaxoSmithKline Fundamentals

Return On Equity	50.81 %
Return On Asset	7.78 %
Profit Margin	15.29 %
Current Valuation	101.34 B
Shares Outstanding	2.51 B
Shares Owned by Insiders	0.01 %
Shares Owned by Institutions	12.17 %
Number of Shares Shorted	8.01 M
Price to Earning	40.70 X
Price to Book	16.78 X
Price to Sales	2.35 X
Revenue	40.01 B
Gross Profit	22.97 B
EBITDA	10.2 B
Net Income	2.46 B
Cash and Equivalents	5.12 B
Cash per Share	2.08 X
Total Debt	36.63 B
Debt to Equity	1.59 %
Current Ratio	0.87 X
Book Value Per Share	2.41 X
Cash Flow from Operations	(5.78 B)
Short Ratio	2.57 X
Earnings Per Share	0.99 X
Price to Earnings To Growth	4.26 X
Number of Employees	99.44 K
Beta	0.42
Market Capitalization	100.84 B
Total Asset	53.45 B
Retained Earnings	4.89 B
Working Capital	3.17 B
Current Asset	16.59 B
Current Liabilities	13.42 B
Z Score	1.2
Five Year Return	5.27 %
Last Dividend Paid	0.472

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.

	2017	2018	2019	2020 (projected)
Receivables	5.67 B	6.08 B	6.87 B	5.97 B
Inventories	5.56 B	5.48 B	5.95 B	5.09 B

Receivables Inventories

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events

Feedback Blog

Made with optimal in San Francisco

2020 Macroaxis LLC

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page